Ketamine-Assisted Psychotherapy

Ketamine-assisted psychotherapy, often called KAP, combines a carefully dosed, medically supervised ketamine session with psychotherapy before and after it. Ketamine is a legal medicine that, at low doses, can shift perception and mood, and in this model the experience is used as an opening for therapeutic work.

The process usually unfolds over a few weeks. It starts with medical and psychological screening and preparation sessions. During a dosing session, you rest with an eye mask and music in a clinic setting while a clinician monitors your safety and a therapist stays nearby. Later integration sessions help you reflect on what came up and apply it in daily life. It differs from recreational use in its screening, dosing, setting, and support.

It is used for treatment-resistant depression, suicidal thoughts, PTSD, anxiety, chronic pain, substance use problems, and distress near the end of life. Clinicians describe the aim as creating a window of mood relief during which therapy may feel more possible.

The evidence is emerging for this combined model. Ketamine itself has moderate to strong evidence for rapid antidepressant effects in depression that has not responded to other options, and a related nasal medicine, esketamine, is approved in the US for that use. Most trials tested the drug alone, so the added value of psychotherapy is not yet well established, and effects can be short-lived.

Ketamine can cause dissociation, nausea, dizziness, and raised blood pressure, and it carries potential for misuse. It is not suitable for everyone, including people with uncontrolled high blood pressure or a history of psychosis, so a physician must screen you. Choose a licensed medical team with clear safety protocols, be cautious about unsupervised at-home use, and keep your existing care and medications in place unless your prescriber advises otherwise.

Ketamine was synthesized in 1962 by Calvin Stevens at Parke-Davis and approved by the US FDA as an anesthetic in 1970. Its rapid antidepressant effects were first reported in a small controlled study by Berman and colleagues at Yale in 2000. In the 1970s and 1980s the Soviet psychiatrist Evgeny Krupitsky, working in Leningrad, combined ketamine with psychotherapy in a program for alcohol dependence, which is often cited as an early forerunner of KAP.

The modern form arose in the United States, where clinicians such as Phil Wolfson and the Ketamine Research Foundation developed protocols that place therapy before, during, or after a supervised dose. The Multidisciplinary Association for Psychedelic Studies published The Ketamine Papers, edited by Wolfson and Glenn Hartelius, in 2016. Esketamine (Spravato), made by Johnson & Johnson, received FDA approval in 2019 for treatment-resistant depression, and off-label clinic use of generic ketamine grew rapidly from the mid-2010s.

KAP clinics now operate in the United States and in countries such as Australia and the United Kingdom, and training programs offered by several organizations cover protocols and safety. No single licensing standard exists for KAP, so practitioner qualifications vary and are debated. Ketamine itself is a prescription medicine, and the FDA has approved esketamine but not generic ketamine for psychiatric use.